TD Cowen initiated coverage of Exscientia plc with a rating of Buy

BofA Securities downgraded Exscientia plc from Buy to Neutral and set a new price target of $9.00 from $11.00 previously

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will focus on first and best-in-class drug discovery and development, demonstrating the ability to find novel insights and dramatically reduce the time and cost of discoveryRecursion will host an update call today, November 20, 2024 at 7:30 a.m. ET / 5:30 a.m. MT / 12:30 p.m. GMT on LinkedIn, X and Youtube SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (NASDAQ:RXRX) and Exscientia has been completed, wi

Salt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) and Exscientia plc (NASDAQ:EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Recursion and Exscientia.  The transaction is expected to close on November 20, 2024, subject to the satisfaction or waiver of the remaining customary closing conditions. Recursion expects to host an update call after the anticipated close on November 20, 2024 at 7:30 a.m. ET /  5:30 a.m MT / 12:30 p.m. GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. Questions can be submitted via this link ahead of

Both programmes demonstrate Exscientia's ability to design highly differentiated, potentially best-in-class molecules Exscientia will receive $15 million for achieving these milestones and is eligible for over $600 million in additional milestone payments for these two programmes as well as high-single-digit to mid-teen royalties Three programmes in the partnership have now advanced through initial milestones with multiple more progressing at earlier stages Exscientia plc (NASDAQ:EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds

Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights efficacy of ‘539 in a preclinical AML model, with limited impact on platelet levels Identified PD biomarkers related to LSD1 inhibitor treatment Exscientia plc (NASDAQ:EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain. "As our precision-designed LSD1 and MALT1 inhibitors continue to progress towards the clinic, we are excited to share new preclinical data from both programmes," said David Hallett, Ph.D., interim Chief Executive Officer and Chief Scientific Officer of Exscientia. "These

Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data demonstrating ENPP1 inhibition as a therapeutic approach for the treatment of patients with hypophosphatasia (HPP) was presented at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting. ASBMR is being held September 27 – 30, 2024 in Toronto, Canada. "From my team's earlier work published in 2002 and 2005, we knew that ENPP1 could be a targetable molecule to modulate TNAP's all-important substrate PPi. I am delighted that we have now been able to de

Exscientia plc (NASDAQ:EXAI) today announced that David Hallett, interim Chief Executive Officer and Chief Scientific Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 7:00 a.m. EDT (12:00 p.m. BST). A live webcast of the fireside chat will be available on the Company's website, under the "Investors & Media" section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation. About Exscientia Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients,

Entered into definitive agreement to combine with Recursion to create a global technology-enabled drug discovery leader with end-to-end capabilities Acquired full rights to GTAEXS617 (CDK7 inhibitor), with initial Phase I monotherapy data expected in 2H24 Launched AWS AI-powered platform to advance drug discovery LSD1 and MALT1 inhibitor programmes continue to progress towards the clinic, on track for 2H24 IND/CTA submissions Exscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2024, are summarised below. "Last week, we announced that Exscientia entered into a

Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone

HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization. Recently, Viva Biotech's portfolio companies have new updates. Keep reading for more details. Nerio Therapeutics, A Viva Biotech's Portfolio Company, Was Successfully Acquired by Boehringer Ingelheim for $1.3 Billion San Diego, California - On July 29, 2024, Boehringer Ingelheim announced the addition of an innovative preclinical program with the acquisition of Nerio Therap

Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025 Exscientia plc (NASDAQ:EXAI) today announced it has reached an agreement to acquire GT Apeiron's share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property. The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. R

S-8 POS - Exscientia plc (0001865408) (Filer)

S-8 POS - Exscientia plc (0001865408) (Filer)

6-K - Exscientia plc (0001865408) (Filer)

25-NSE - Exscientia plc (0001865408) (Subject)

6-K - Exscientia plc (0001865408) (Filer)

6-K - Exscientia plc (0001865408) (Filer)

6-K - Exscientia plc (0001865408) (Filer)

6-K - Exscientia plc (0001865408) (Filer)

6-K - Exscientia plc (0001865408) (Filer)

6-K/A - Exscientia plc (0001865408) (Filer)

SC 13G/A - Exscientia plc (0001865408) (Subject)

SC 13D/A - Exscientia plc (0001865408) (Subject)

SC 13G/A - Exscientia plc (0001865408) (Subject)

SC 13G - Exscientia plc (0001865408) (Subject)

SC 13G - Exscientia plc (0001865408) (Subject)

SC 13G - Exscientia plc (0001865408) (Subject)

SC 13G - Exscientia plc (0001865408) (Subject)

Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to commence in late 2024/early 2025 Exscientia plc (NASDAQ:EXAI) today announced it has reached an agreement to acquire GT Apeiron's share of its oral CDK7 inhibitor programme, gaining full control of GTAEXS617 (‘617) and all related intellectual property. The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. R

Positive early Phase 1 results for BMS-partnered programme ‘4318 (PKC-theta inhibitor) GTAEXS617 (CDK7 inhibitor) initial Phase I data expected in 2H24 LSD1 and MALT1 inhibitor programmes expected to advance into clinic in 2H24 and early 2025, respectively AI-design integration enhanced with full experiment automation driving towards maximum speed, quality and autonomous drug design Leveraging technology advancements and streamlining operations to realise annualised savings of $40 million Exscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below. Exscient

Company to host conference call and webcast on May 21, 2024, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 (800) 358 0970 (U.K.), +1 (646) 960 0857 (International)

Exscientia plc (NASDAQ:EXAI) Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below. Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT. "In 2023, we significantly expanded our technological capabilities with the opening of our automation facility, concentrated our internal research on high value oncology targets and steadily progressed multiple new and existing programmes with our large pharma partners," said Dr. David Hallett, interim Chief Executive Officer and Chief Scientific Officer of Exscientia. "In 2024 we will continue to

Company to host conference call and webcast on March 21, 2024, at 12:30 p.m. GMT / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 596 4144 (U.S.), +44 (800) 358 0970 (U.K.), +1 (646)

Exscientia plc (NASDAQ:EXAI): Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below. Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST. "At Exscientia, we are laser-focused on building an engine that designs and develops high impact medicines that have the potential to transform patients' lives," said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. "We are continuing to build out a highly-differentiated internal oncology pipeline, particularly with clinical and IND-enabling stage programmes targeting

Company to host conference call and webcast on November 9, 2023, at 1:30 p.m. GMT / 8:30 a.m. EST Exscientia plc (NASDAQ:EXAI) will report financial results for the third quarter ended September 30, 2023, on Thursday, November 9, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. GMT / 8:30 a.m. EST to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (Int

Exscientia plc (NASDAQ:EXAI) Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the second quarter and first half 2023, are summarised below. Exscientia will host a conference call Thursday, August 10 at 1:30 p.m. BST / 8:30 a.m. EDT. "In the first half of 2023, four molecules precision-designed by Exscientia advanced further into clinical trials, a significant achievement as we progress our growing pipeline," said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. "Most recently, we announced the dosing of the first patient in ELUCIDATE, a Phase 1/2 trial of our CDK7 inhibitor GTAEXS617 (‘

Company to host conference call and webcast on August 10, 2023, at 1:30 p.m. BST / 8:30 a.m. EDT Exscientia plc (NASDAQ:EXAI) will report financial results for the second quarter ended June 30, 2023, on Thursday August 10, 2023, before the open of U.S. markets. The Company will host a conference call and webcast at 1:30 p.m. BST / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the "Investors and Media" section of the Company's website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (Internatio

Exscientia plc (NASDAQ:EXAI) Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2023, are summarised below. Exscientia will host a conference call Wednesday, May 24 at 1:30 p.m. BST / 8:30 a.m. EDT. "With our sixth AI-designed compound reaching the clinical development stage plus two more in active IND/CTA-enabling studies, Exscientia's pipeline of wholly owned and partnered drug candidates is progressing rapidly," said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. "Most recently, the first patient has been dosed in our IGNITE Phase 1/2 clinical trial. While many peop

The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of '617 in advanced solid tumours. Recruitment for the trial is progressing well with monotherapy dose escalation data on track to readout in the second half of 2024. In late 2024/early 2025, the study will transition to a combination dose escalation phase. The first tumour type to be explored in this portion of the study is expected to be HR+/HER2- breast cancer patients that have progressed on CDK4/6 inhibitors, assessing ‘617 in combination with a selective estrogen receptor degrader (SERD).  Exscientia will pay GT Apeiron $10 million in upfront cash, $10 million in

The platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia's ability to deliver high quality drug candidates at faster speed and lower cost.

TD Cowen analyst Brendan Smith initiates coverage on Exscientia (NASDAQ:EXAI) with a Buy rating.

U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday's session on reports the company will partner with Baidu for mapping and navigation for Full Self-Driving in China. Tesla shares jumped 10.5% to $185.94 on Monday. Here are some other big stocks recording gains in today's session. Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares surged 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash. ImmunityBio, Inc. (NASDAQ:IBRX) shares rose 36.3% to $10.02. ImmunityBio shares jumped around 44% on Friday after the company annou

Morgan Stanley analyst Vikram Purohit maintains Exscientia (NASDAQ:EXAI) with a Equal-Weight and maintains $7 price target.

Shares of Ulta Beauty, Inc. (NASDAQ:ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook. Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers ARCA biopharma, Inc. (NASDAQ:ABIO) climbed 108% to $3.5549 after the company and Oruka Therapeutics announced a merger agreement. Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares gained 89% to $0.1906 after the company entered a merger agreement with TuHURA Biosciences. Next Technology Holding Inc. (NASDAQ:NXTT) rose 57.4% to $6.42. Vanda Ph

– SEC Filing

Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone

— AI drug design pioneer John P. Overington, Ph.D., appointed to Chief Technology Officer to maximise strategic technology integration and application — — Maria-Louise Fjällskog, M.D., Ph.D., appointed interim Chief Medical Officer, adding extensive oncology drug development expertise to execute robust clinical strategy on Exscientia's internal oncology pipeline — Exscientia plc (NASDAQ:EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development. Appointed to Chief Technology Officer, John P. Overington, Ph.D.,

Renowned technology champion to strengthen company's development of precision medicine and clinical innovation platforms Exscientia plc (NASDAQ:EXAI) today announced the appointment of Parker Moss as Executive Vice President, Corporate Development, effective January, 2024. In this newly established role, Parker will lead the creation and execution of a focused corporate development strategy to strengthen further and create new market opportunities for the company's precision medicine, clinical and tech innovation platforms, with a particular focus on oncology. Reporting to CEO Andrew Hopkins, he will help the company's Executive Leadership Team to identify and shape new business opportuni

— Renowned thought leader in computational biology and data science for cancer research — — Over 180 publications on the evolutionary dynamics of cancer initiation, progression, response to therapy and emergence of resistance — Exscientia plc (NASDAQ:EXAI) today announced the appointment of Professor Franziska Michor, Ph.D. to its Board of Directors. Prof. Michor is a professor of Computational Biology in the Department of Data Science at the Dana-Farber Cancer Institute, in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health, and in the Department of Stem Cell and Regenerative Biology at Harvard University. The Board now comprises seven directors. "We are

Moelis & Company (NYSE:MC), a leading global independent investment bank, today announced the appointment of Elizabeth Crain to Vice Chair and the promotion of Kate Pilcher Ciafone to Chief Operating Officer (COO), both effective October 1, 2023. Elizabeth Crain is a Founding Partner at Moelis & Company where she has led the Firm's global strategy and operations as COO since 2007. Elizabeth has been an integral member of the Firm's leadership team since its inception driving the Firm's growth and expansion of its advisory capabilities. She has been in the investment banking and private equity industries for almost 35 years as a banker, principal and operating executive. In her new role as

Exscientia plc (NASDAQ:EXAI) today announced the appointment of Michael Krams, M.D., as its Chief Quantitative Medicine Officer. In this newly created role, Dr. Krams will lead clinical development strategy for Exscientia's portfolio of investigational medicines. Exscientia's drug discovery platform utilises patient-based translational models and AI-driven molecule design to optimise drug candidates for specific patient populations. As part of these efforts, Dr. Krams will drive work to improve trial design and patient selection within clinical trials to maximise clinical success and patient benefit. "We want to be as innovative in the clinic as we have been in drug discovery. Mike is a pr